

March 2026

MEDPACE
Clinical Pharmacology

OR-ARI-DDI-01

Study Inpatient dates:

Mar 24-27, 2026
Mar 31-Apr 03, 2026
Apr 07-10, 2026

Follow-Up Phone Call:

Apr 15, 2026

Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the informed consent. Refrain from egg donation **throughout the study and for 30 days after last dose of study drug (Day 15)** or refrain from sperm donation **throughout the study and for 90 days after last dose of study drug (Day 15)**.
- Abstain from prescription medications (not including allowed birth control) and over-the-counter medications (including vitamins, minerals, analgesics, herbal products, homeopathic medicines, and dietary supplements) **within 14 days prior to first admission (Day -1) and throughout the study until final discharge (Day 17)** unless otherwise approved by the Investigator.
- Avoid smoking or use of nicotine products (including cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, topical nicotine patches, nicotine gum, and nicotine lozenges) **within 6 months prior to first admission (Day -1) and throughout the study until final discharge (Day 17)**.
- Avoid recreational drugs including products containing THC and drugs of abuse **from Screening (urine test for drugs of abuse needs to be negative at Screening) and throughout the study until final discharge (Day 17)**.
- Avoid consumption of alcohol or caffeine/xanthine for **48 hours prior to each admission (Days -1, 7, and 14) until final discharge (Day 17)**.
- Refrain from exercise or sports **within 72 hours prior to dosing (Days 1, 8, and 15) until 36 hours after dosing**.
- Avoid any special diets (ex: therapeutic, experimental, low carb, weight-loss diet, dairy-free, gluten-free, vegan, and vegetarian) for **4 weeks before the first admission (Day -1) and throughout the study**.
- Avoid donation of ≥ 500 mL of blood **within 30 days prior to first admission (Day -1) and throughout the study until 30 days after final discharge (Day 17)**. Avoid donation of ≥ 500 mL of plasma **within 14 days prior to first admission (Day -1) and throughout the study until 30 days after final discharge (Day 17)**. Avoid receipt of blood products **within 2 months prior to first admission (Day -1)**.

Reminder: COVID-19 rapid antigen, breath alcohol, and urine drug tests at each Admission (Days -1, 7, and 14).

***payment to occur within 48 hours after payment visit day**

Sun	Mon	Tue	Wed	Thu	Fri	Sat
1	2	3	4	5	6	7
8	9	10 Begin medication and plasma donation restrictions	11	12	13	14
15	16	17	18	19	20	21
22 Begin alcohol, caffeine, xanthine, and exercise restrictions	23	24 Day -1 Admission	25 Day 1 Dose	26 Day 2 Inpatient	27 Day 3 Discharge Payment #1*	28
29 Begin alcohol, caffeine, xanthine, and exercise restrictions	30	31 Day 7 Admission				

April 2026

MEDPACE
Clinical Pharmacology

OR-ARI-DDI-01

Study Inpatient dates:

Mar 24-27, 2026
Mar 31-Apr 03, 2026
Apr 07-10, 2026

Follow-Up Phone Call:

Apr 15, 2026

Sun	Mon	Tue	Wed	Thu	Fri	Sat
			1 Day 8 Dose	2 Day 9 Inpatient	3 Day 10 Discharge Payment #2*	4
5 Begin alcohol, caffeine, xanthine, and exercise restrictions	6	7 Day 14 Admission	8 Day 15 Dose	9 Day 16 Inpatient	10 Day 17 Discharge Payment #3*	11
12	13	14	15 Day 22 Follow-Up Phone Call Payment #4*	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30		

Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the informed consent. Refrain from egg donation **throughout the study and for 30 days after last dose of study drug (Day 15)** or refrain from sperm donation **throughout the study and for 90 days after last dose of study drug (Day 15)**.
- Abstain from prescription medications (not including allowed birth control) and over-the-counter medications (including vitamins, minerals, analgesics, herbal products, homeopathic medicines, and dietary supplements) **within 14 days prior to first admission (Day -1) and throughout the study until final discharge (Day 17)** unless otherwise approved by the Investigator.
- Avoid smoking or use of nicotine products (including cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, topical nicotine patches, nicotine gum, and nicotine lozenges) **within 6 months prior to first admission (Day -1) and throughout the study until final discharge (Day 17)**.
- Avoid recreational drugs including products containing THC and drugs of abuse **from Screening (urine test for drugs of abuse needs to be negative at Screening) and throughout the study until final discharge (Day 17)**.
- Avoid consumption of alcohol or caffeine/xanthine for **48 hours prior to each admission (Days -1, 7, and 14) until final discharge (Day 17)**.
- Refrain from exercise or sports **within 72 hours prior to dosing (Days 1, 8, and 15) until 36 hours after dosing**.
- Avoid any special diets (ex: therapeutic, experimental, low carb, weight-loss diet, dairy-free, gluten-free, vegan, and vegetarian) for **4 weeks before the first admission (Day -1) and throughout the study**.
- Avoid donation of ≥ 500 mL of blood **within 30 days prior to first admission (Day -1) and throughout the study until 30 days after final discharge (Day 17)**. Avoid donation of ≥ 500 mL of plasma **within 14 days prior to first admission (Day -1) and throughout the study until 30 days after final discharge (Day 17)**. Avoid receipt of blood products **within 2 months prior to first admission (Day -1)**.

Reminder: COVID-19 rapid antigen, breath alcohol, and urine drug tests at each Admission (Days -1, 7, and 14).

***payment to occur within 48 hours after payment visit day**